Incidence of severe urinary tract infections not increased by initiating sodium–glucose cotransporter 2 inhibitors

Documenti analoghi

• Sodium-glucose cotransporter 2 inhibitors and the risk of severe urinary tract infections
  di: Dave, Chintan V., et al.
  Pubblicazione: (2019)
• The risk for urinary tract infections with sodium-glucose cotransporter 2 inhibitors: no longer a cause of concern?
  di: Sarafidis, Pantelis A, et al.
  Pubblicazione: (2019)
• Reduction in the incidence of myocardial infarction with sodium–glucose linked cotransporter-2 inhibitors: evident and plausible
  di: Gilbert, Richard E., et al.
  Pubblicazione: (2019)
• Incidence and risk of vaginal candidiasis associated with sodium–glucose cotransporter 2 inhibitors in real‐world practice for women with type 2 diabetes
  di: Yokoyama, Hiroki, et al.
  Pubblicazione: (2018)
• Increased Hematocrit During Sodium-Glucose Cotransporter-2 Inhibitor Therapy
  di: Heyman, Samuel N., et al.
  Pubblicazione: (2017)